Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMEL1 | Q495T6 | 2/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 8/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 8/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
| ▸ | MME | P08473 | 1/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6473535 | 0.83 | AOC3 (0.43) | MMEL1HDAC1HDAC6 | |
| SCHEMBL6183283 | 0.83 | MME (0.46) | MMEL1FAAHMMEFFAR1 | |
| SCHEMBL6473073 | 0.79 | EPHX2 (0.38) | HDAC1HDAC6EPHX2FAAHPPARG | |
| SCHEMBL6473082 | 0.79 | EPHX2 (0.38) | HDAC1HDAC6EPHX2FAAHPPARG | |
| SCHEMBL6182804 | 0.72 | TDP1 (0.40) | EPHX2FAAHFFAR1PPARGPPARA | |
| SCHEMBL5761436 | 0.70 | PPARG (0.46) | FFAR1PPARGPPARA | |
| SCHEMBL5760267 | 0.68 | PPARG (0.47) | FFAR1PPARGPPARA | |
| SCHEMBL25542954 | 0.68 | HDAC1 (0.61) | HDAC1HDAC6EPHX2 | |
| SCHEMBL5355946 | 0.68 | KDM4C (0.42) | FFAR1 | |
| SCHEMBL3947105 | 0.68 | PPARG (0.38) | PPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6927228-B2 | Biphenyl compounds usefuf in treatment of human and veterinary medicines such as dermatology, cardivovascular diseases, immune diseases or diseases associated with lipid metabolisms, or in cosmetic formulation | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2005-08-09 | — | — | US | disclosed |
| US-20040039038-A1 | Biaromatic compound activators of PPARy-type receptors | GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) | 2004-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040039038-A1 | Biaromatic compound activators of PPARy-type receptors | PPARG, PPARA, PPARD | MMEL1 3380/4885HDAC1 502/4885HDAC6 1271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.